Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.

Autor: Ali S; European Medicines Agency, Amsterdam, The Netherlands., Kjeken R; Norwegian Medicines Agency, Oslo, Norway., Niederlaender C; Medicines and Healthcare Products Regulatory Agency, London, United Kingdom., Markey G; Medicines and Healthcare Products Regulatory Agency, London, United Kingdom., Saunders TS; Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands.; Norwegian Medicines Agency, Oslo, Norway., Opsata M; Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands.; Norwegian Medicines Agency, Oslo, Norway., Moltu K; Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands.; Norwegian Medicines Agency, Oslo, Norway., Bremnes B; Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands.; Norwegian Medicines Agency, Oslo, Norway., Grønevik E; Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands.; Norwegian Medicines Agency, Oslo, Norway., Muusse M; Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands.; Norwegian Medicines Agency, Oslo, Norway., Håkonsen GD; Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands.; Norwegian Medicines Agency, Oslo, Norway., Skibeli V; Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands.; Norwegian Medicines Agency, Oslo, Norway., Kalland ME; Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands.; Norwegian Medicines Agency, Oslo, Norway., Wang I; Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands.; Norwegian Medicines Agency, Oslo, Norway., Buajordet I; Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands.; Norwegian Medicines Agency, Oslo, Norway., Urbaniak A; Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands.; Norwegian Medicines Agency, Oslo, Norway., Johnston J; Medicines and Healthcare Products Regulatory Agency, London, United Kingdom., Rantell K; Medicines and Healthcare Products Regulatory Agency, London, United Kingdom., Kerwash E; Medicines and Healthcare Products Regulatory Agency, London, United Kingdom., Schuessler-Lenz M; Committee for Advanced Therapies, European Medicines Agency, Amsterdam, The Netherlands.; Paul-Ehrlich-Institut, Langen, Germany., Salmonson T; Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands.; Medical Products Agency, Uppsala, Sweden., Bergh J; Scientific Advisory Group, European Medicines Agency, Amsterdam, The Netherlands.; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.; Karolinska University Hospital BioClinicum, New Karolinska Hospital, Solna, Sweden., Gisselbrecht C; Scientific Advisory Group, European Medicines Agency, Amsterdam, The Netherlands.; Institut d'Hématologie, Hôpital Saint Louis, Paris, France., Tzogani K; European Medicines Agency, Amsterdam, The Netherlands., Papadouli I; European Medicines Agency, Amsterdam, The Netherlands., Pignatti F; European Medicines Agency, Amsterdam, The Netherlands.

Publikováno v: The oncologist [Oncologist] 2020 Feb; Vol. 25 (2), pp. e321-e327. Date of Electronic Publication: 2019 Oct 16.